# GSK Acquires Nuvalent for $10.6 Billion to Build Lung Cancer Franchise

> ma · REPORTED · 2026-06-09

GSK agreed on June 9, 2026 to acquire Boston-based Nuvalent for $10.6 billion ($124 per share, a 40% premium), gaining two late-stage NSCLC drugs—zidesamtinib (ROS1) and neladalkib (ALK)—both under FDA review with 2026 decision dates, plus a HER2 inhibitor in Phase I. This is GSK's largest deal in over a decade and its third acquisition of 2026.

- Company: GSK / Nuvalent
- Sector: oncology
- Primary source: https://investors.nuvalent.com/2026-06-09-GSK-enters-agreement-to-acquire-Nuvalent,-Inc

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.